Pre-order Enquiry
Request Free Sample
Global Dry Powder Inhaler Device Market Research Report 2022
SKU ID : QYR-21624688 | Publishing Date : 06-Sep-2022 | No. of pages : 95
A dry powder inhaler (DPI) is a device that delivers medication to the lungs in the form of a dry powder. DPIs are commonly used to treat respiratory diseases such as asthma, bronchitis, emphysema and COPD although DPIs (such as inhalable insulin Afrezza) have also been used in the treatment of diabetes mellitus.
Due to the COVID-19 pandemic, the global Dry Powder Inhaler Device market size is estimated to be worth US$ 786.6 million in 2021 and is forecast to a readjusted size of US$ 1103.8 million by 2028 with a CAGR of 4.9% during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Dry Powder Inhaler Device market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Dry Powder Inhaler Device landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Chiesi, etc. are the key players in the global Dry Powder Inhaler Device market. Top 4 took up more than 30% of the global market.
From the view of region, USA have a larger consumption market share which account for about 35% of total share. Europe hold a market share of about 25%. In addition, Asia Pacific is also play important role in Global market.
Dry Powder Inhaler Device main application area is Asthma This sector hold a market share of over 80%. Then followed by the COPD.
According to the Segmentation of types, all the market of Dry Powder Inhaler Device can be divided as follows: Multi-dose, Single-dose.
This report focuses on Dry Powder Inhaler Device volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Dry Powder Inhaler Device market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Dry Powder Inhaler Device Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Single Dose
Multi Dose
Segment by Application
Asthma
COPD
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
GlaxoSmithKline
AstraZeneca
Boehringer Ingelheim
Chiesi
Cipla
3M
Hovione
Mannkind
Mylan
Novartis
Schering/Merck
Teva
Vectura
Due to the COVID-19 pandemic, the global Dry Powder Inhaler Device market size is estimated to be worth US$ 786.6 million in 2021 and is forecast to a readjusted size of US$ 1103.8 million by 2028 with a CAGR of 4.9% during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Dry Powder Inhaler Device market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Dry Powder Inhaler Device landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Chiesi, etc. are the key players in the global Dry Powder Inhaler Device market. Top 4 took up more than 30% of the global market.
From the view of region, USA have a larger consumption market share which account for about 35% of total share. Europe hold a market share of about 25%. In addition, Asia Pacific is also play important role in Global market.
Dry Powder Inhaler Device main application area is Asthma This sector hold a market share of over 80%. Then followed by the COPD.
According to the Segmentation of types, all the market of Dry Powder Inhaler Device can be divided as follows: Multi-dose, Single-dose.
This report focuses on Dry Powder Inhaler Device volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Dry Powder Inhaler Device market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Dry Powder Inhaler Device Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Single Dose
Multi Dose
Segment by Application
Asthma
COPD
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
GlaxoSmithKline
AstraZeneca
Boehringer Ingelheim
Chiesi
Cipla
3M
Hovione
Mannkind
Mylan
Novartis
Schering/Merck
Teva
Vectura
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Request Sample
Request Discount
